Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB
The ability of a phagocyte to perform multiple rounds of phagocytosis of ACs in a relatively short timecalled continuous efferocytosisis essential in scenarios where the ACs:phagocytes ratio is high, such as after an acute inflammatory process or tissue injury
The approval was backed by data from the Phase II DESTINY-PanTumor02 trial, which enrolled nearly 470 patients with HER2-positve solid tumors
[DOI] [PubMed] [Google Scholar] 67.Mats J.M., Campos-Sandoval J.A., de Los Santos-Jimnez J., Mrquez J
The rate of treatment discontinuation due to adverse events was comparable to what has been observed in trials of GLP-1 monotherapy
2021;12:e0212121